Skip to main content
Top
Published in: Journal of Clinical Immunology 8/2015

01-11-2015 | Original Article

Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection

Authors: Cullen M. Dutmer, Edwin J. Asturias, Christiana Smith, Megan K. Dishop, D. Scott Schmid, William J. Bellini, Irit Tirosh, Yu Nee Lee, Luigi D. Notarangelo, Erwin W. Gelfand

Published in: Journal of Clinical Immunology | Issue 8/2015

Login to get access

Abstract

Purpose

Hypomorphic mutations in RAG1 and RAG2 are associated with significant clinical heterogeneity and symptoms of immunodeficiency or autoimmunity may be late in appearance. As a result, immunosuppressive medications may be introduced that can have life-threatening consequences. We describe a previously healthy 13-month-old girl presenting with rash and autoimmune hemolytic anemia, while highlighting the importance of vigilance and consideration of an underlying severe immunodeficiency disease prior to instituting immunosuppressive therapy.

Methods

Given clinical deterioration of the patient and a temporal association with recently administered vaccinations, virus genotyping was carried out via 4 real-time Forster Resonance Energy Transfer PCR protocols targeting vaccine-associated single nucleotide polymorphisms. Genomic DNA was extracted from whole blood and analyzed via the next-generation sequencing method of sequencing-by-synthesis. Immune function studies included immunophenotyping of peripheral blood lymphocytes, mitogen-induced proliferation and TLR ligand-induced production of TNFα. Analysis of recombination activity of wild-type and mutant RAG2 constructs was performed.

Results

Virus genotyping revealed vaccine-strain VZV, mumps, and rubella. Next-generation sequencing identified heterozygosity for RAG2 R73H and P180H mutations. Profound lymphopenia was associated with intense corticosteroid therapy, with some recovery after steroid reduction. Residual, albeit low, RAG2 protein activity was demonstrated.

Conclusions

Because of the association of RAG deficiency with late-onset presentation and autoimmunity, live virus vaccination and immunosuppressive therapies are often initiated and can result in negative consequences. Here, hypomorphic RAG2 mutations were linked to disseminated vaccine-strain virus infections following institution of corticosteroid therapy for autoimmune hemolytic anemia.
Literature
1.
go back to reference Hesslein DG, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol. 2001;78:169–232.CrossRefPubMed Hesslein DG, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol. 2001;78:169–232.CrossRefPubMed
3.
go back to reference Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274:97–9.CrossRefPubMed Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274:97–9.CrossRefPubMed
4.
go back to reference Avila EM, Uzel G, Hsu A, Milner JD, Holland SM. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126:1248–52.CrossRef Avila EM, Uzel G, Hsu A, Milner JD, Holland SM. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126:1248–52.CrossRef
5.
go back to reference Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol. 2008;122:1082–6.CrossRefPubMed Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol. 2008;122:1082–6.CrossRefPubMed
6.
go back to reference de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291–9.PubMedCentralCrossRefPubMed de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291–9.PubMedCentralCrossRefPubMed
7.
go back to reference Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358:2030–8.CrossRefPubMed Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358:2030–8.CrossRefPubMed
8.
go back to reference De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116:1263–71.PubMedCentralCrossRefPubMed De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116:1263–71.PubMedCentralCrossRefPubMed
9.
go back to reference Kuijpers TW, IJspeert H, van Leeuwen EM, Jansen MH, Hazenberg MD, Weijer KC, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG. Blood. 2011;117:5892–6.CrossRefPubMed Kuijpers TW, IJspeert H, van Leeuwen EM, Jansen MH, Hazenberg MD, Weijer KC, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG. Blood. 2011;117:5892–6.CrossRefPubMed
10.
go back to reference Abraham RS, Recher M, Giliani S, Walter JE, Lee YN, Frugoni F, et al. Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation. J Allergy Clin Immunol. 2013;131:1421–3.PubMedCentralCrossRefPubMed Abraham RS, Recher M, Giliani S, Walter JE, Lee YN, Frugoni F, et al. Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation. J Allergy Clin Immunol. 2013;131:1421–3.PubMedCentralCrossRefPubMed
11.
go back to reference Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132:969–71.CrossRefPubMed Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132:969–71.CrossRefPubMed
12.
go back to reference Abolhassani H, Wang N, Aghamohammadi A, Rezaei N, Lee YN, Frugoni F, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:1375–80.CrossRefPubMed Abolhassani H, Wang N, Aghamohammadi A, Rezaei N, Lee YN, Frugoni F, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:1375–80.CrossRefPubMed
13.
go back to reference Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 deficiency may present clinically as selective IgA deficiency. J Clin Immunol. 2015;35:280–8.CrossRefPubMed Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 deficiency may present clinically as selective IgA deficiency. J Clin Immunol. 2015;35:280–8.CrossRefPubMed
14.
go back to reference Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014;133:1099–108.PubMedCentralCrossRefPubMed Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014;133:1099–108.PubMedCentralCrossRefPubMed
15.
go back to reference IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133:1124–33.CrossRefPubMed IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133:1124–33.CrossRefPubMed
16.
go back to reference Smith C, Dutmer CM, Schmid DS, Bellini WJ, Gelfand EW, Asturias EJ. A toddler with rash, encephalopathy, and hemolytic anemia. J Pediatr Infect Dis. 2015. doi:10.1093/jpids/piv032. Smith C, Dutmer CM, Schmid DS, Bellini WJ, Gelfand EW, Asturias EJ. A toddler with rash, encephalopathy, and hemolytic anemia. J Pediatr Infect Dis. 2015. doi:10.​1093/​jpids/​piv032.
17.
go back to reference Asai E, Wada T, Sakakibara Y, Toga A, Toma T, Shimizu T, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol. 2011;138:172–7.CrossRefPubMed Asai E, Wada T, Sakakibara Y, Toga A, Toma T, Shimizu T, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol. 2011;138:172–7.CrossRefPubMed
18.
go back to reference Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM, et al. Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol. 2014;133:1225–7.PubMedCentralCrossRefPubMed Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM, et al. Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol. 2014;133:1225–7.PubMedCentralCrossRefPubMed
19.
go back to reference Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124:522–7.CrossRefPubMed Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124:522–7.CrossRefPubMed
20.
go back to reference Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.PubMedCentralCrossRefPubMed Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.PubMedCentralCrossRefPubMed
21.
go back to reference Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39:194–205.CrossRefPubMed Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39:194–205.CrossRefPubMed
22.
go back to reference Salt BH, Niemela JE, Pandey R, Hanson EP, Deering RP, Quinones R, et al. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J Allergy Clin Immunol. 2008;121(4):976–82.PubMedCentralCrossRefPubMed Salt BH, Niemela JE, Pandey R, Hanson EP, Deering RP, Quinones R, et al. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J Allergy Clin Immunol. 2008;121(4):976–82.PubMedCentralCrossRefPubMed
23.
go back to reference Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133:880–2.PubMedCentralCrossRefPubMed Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133:880–2.PubMedCentralCrossRefPubMed
24.
go back to reference Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.CrossRefPubMed Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.CrossRefPubMed
25.
go back to reference Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol. 2010;125:209–16.CrossRefPubMed Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol. 2010;125:209–16.CrossRefPubMed
26.
go back to reference Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMed Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMed
27.
go back to reference Russell AF, Parrino J, Fisher Jr CL, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33:3129–34.CrossRefPubMed Russell AF, Parrino J, Fisher Jr CL, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33:3129–34.CrossRefPubMed
28.
go back to reference Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, et al. Fatal varicella due to the vaccine strain varicella-zoster virus. Hum Vaccin Immunother. 2014;10:146–9.PubMedCentralCrossRefPubMed Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, et al. Fatal varicella due to the vaccine strain varicella-zoster virus. Hum Vaccin Immunother. 2014;10:146–9.PubMedCentralCrossRefPubMed
29.
go back to reference Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet. 2007;369:1232.CrossRefPubMed Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet. 2007;369:1232.CrossRefPubMed
30.
go back to reference Woo EJ. Letter to the editor: fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother. 2015;11:679.CrossRefPubMed Woo EJ. Letter to the editor: fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother. 2015;11:679.CrossRefPubMed
31.
go back to reference Levy O, Orange JS, Hibberd P, Steinberg S, LaRussa P, Weinberg A, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 2003;188:948–53.CrossRefPubMed Levy O, Orange JS, Hibberd P, Steinberg S, LaRussa P, Weinberg A, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 2003;188:948–53.CrossRefPubMed
32.
go back to reference Schuetz C, Neven B, Dvorak CC, Leroy S, Ege MJ, Pannicke U, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123:281–9.PubMedCentralCrossRefPubMed Schuetz C, Neven B, Dvorak CC, Leroy S, Ege MJ, Pannicke U, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123:281–9.PubMedCentralCrossRefPubMed
Metadata
Title
Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection
Authors
Cullen M. Dutmer
Edwin J. Asturias
Christiana Smith
Megan K. Dishop
D. Scott Schmid
William J. Bellini
Irit Tirosh
Yu Nee Lee
Luigi D. Notarangelo
Erwin W. Gelfand
Publication date
01-11-2015
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 8/2015
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0207-8

Other articles of this Issue 8/2015

Journal of Clinical Immunology 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.